Brendan M Everett Selected Research

Atherosclerosis

1/2019	Novel Antiatherosclerotic Therapies.
1/2019	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
10/2018	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
10/2017	Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
1/2009	Interleukin-18 and the risk of future cardiovascular disease among initially healthy women.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brendan M Everett Research Topics

Disease

28	Cardiovascular Diseases (Cardiovascular Disease) 01/2024 - 01/2009
23	Type 2 Diabetes Mellitus (MODY) 03/2024 - 09/2009
21	Myocardial Infarction 03/2024 - 06/2011
15	Inflammation (Inflammations) 02/2023 - 07/2010
14	Heart Failure 03/2024 - 12/2014
13	Stroke (Strokes) 03/2024 - 12/2006
8	Thrombosis (Thrombus) 01/2023 - 02/2007
5	Atrial Fibrillation 10/2022 - 07/2010
5	Atherosclerosis 01/2019 - 01/2009
4	Coronary Disease (Coronary Heart Disease) 01/2019 - 08/2006
3	Chronic Renal Insufficiency 01/2024 - 01/2018
3	COVID-19 01/2023 - 08/2021
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020 - 02/2015
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 08/2013
3	Acute Coronary Syndrome 01/2020 - 08/2015
3	Diabetes Mellitus 01/2019 - 06/2011
3	Peripheral Arterial Disease 01/2019 - 01/2018
3	Hypertension (High Blood Pressure) 01/2016 - 04/2008
3	Ischemic Stroke 01/2016 - 12/2006
3	Thrombocytopenia (Thrombopenia) 02/2007 - 08/2006
2	Neoplasms (Cancer) 03/2024 - 10/2017
2	Gout 01/2023 - 10/2018
2	Hemorrhage 01/2023 - 08/2006
2	Venous Thromboembolism 01/2023 - 11/2022
2	Hypertriglyceridemia 11/2022 - 12/2018
2	Critical Illness (Critically Ill) 08/2021 - 08/2021
2	Rheumatoid Arthritis 01/2020 - 08/2013
2	Dyslipidemias (Dyslipidemia) 01/2019 - 12/2018
2	Unstable Angina 10/2018 - 01/2018
2	Infections 10/2017 - 01/2017
2	Myocardial Ischemia (Ischemic Heart Diseases) 11/2015 - 08/2015
1	Acute Kidney Injury (Acute Renal Failure) 03/2024
1	Urinary Bladder Neoplasms (Bladder Cancer) 03/2024
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 03/2024
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2024
1	Non-alcoholic Fatty Liver Disease 11/2022
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2021
1	Rheumatic Diseases (Rheumatism) 01/2020
1	Skin Neoplasms (Skin Cancer) 01/2019

Drug/Important Bio-Agent (IBA)

16	C-Reactive ProteinIBA 01/2023 - 12/2006
13	canakinumab FDA Link 01/2023 - 01/2017
11	Biomarkers (Surrogate Marker)IBA 01/2023 - 12/2006
10	LipidsIBA 02/2023 - 12/2006
9	Glucose (Dextrose)FDA LinkGeneric 03/2024 - 09/2009
8	TroponinIBA 01/2021 - 02/2015
7	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019 - 01/2010
6	LDL CholesterolIBA 11/2022 - 12/2006
6	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2020 - 03/2013
5	omega-Chloroacetophenone (Mace)IBA 03/2024 - 10/2018
5	HDL CholesterolIBA 11/2022 - 12/2006
5	Heparin (Liquaemin)FDA LinkGeneric 08/2021 - 08/2006
5	InterleukinsIBA 10/2020 - 01/2009
5	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 08/2013
5	pro-brain natriuretic peptide (1-76)IBA 01/2020 - 10/2014
5	Monoclonal AntibodiesIBA 01/2019 - 01/2017
5	Troponin T (Troponin T1)IBA 10/2018 - 06/2011
4	CholesterolIBA 11/2022 - 12/2006
4	SodiumIBA 10/2022 - 11/2021
4	Natriuretic PeptidesIBA 01/2022 - 03/2013
4	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2018
4	Interleukin-6 (Interleukin 6)IBA 01/2019 - 09/2009
4	Rosuvastatin Calcium (Crestor)FDA Link 05/2015 - 01/2010
3	empagliflozinIBA 03/2024 - 10/2022
3	Metformin (Glucophage)FDA LinkGeneric 01/2024 - 09/2009
3	Insulin Glargine (Lantus)FDA Link 01/2024 - 09/2009
3	Sitagliptin Phosphate (Januvia)FDA Link 01/2024 - 10/2022
3	Sodium-Glucose Transport ProteinsIBA 01/2023 - 01/2018
3	Hypoglycemic Agents (Hypoglycemics)IBA 11/2020 - 12/2017
3	Troponin IIBA 01/2020 - 05/2015
3	InflammasomesIBA 12/2019 - 10/2017
3	oxidized low density lipoproteinIBA 12/2018 - 12/2006
3	AntibodiesIBA 02/2007 - 08/2006
2	Liraglutide FDA Link 01/2024 - 10/2022
2	(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA 11/2022 - 12/2018
2	Triglycerides (Triacylglycerol)IBA 11/2022 - 12/2018
2	Sodium-Glucose Transporter 2 InhibitorsIBA 11/2021 - 01/2018
2	CanagliflozinIBA 01/2020 - 01/2018
2	Lipoproteins (Lipoprotein)IBA 01/2019 - 12/2018
2	ApolipoproteinsIBA 01/2019 - 05/2009
2	Insulin (Novolin)FDA Link 12/2017 - 09/2009
2	Genetic Markers (Genetic Marker)IBA 04/2014 - 08/2013
2	Lipoprotein(a)IBA 02/2014 - 05/2009
2	Platelet Factor 4IBA 08/2006 - 08/2006
1	glimepiride (Amarel)FDA LinkGeneric 01/2024
1	apixabanIBA 01/2023
1	HDL LipoproteinsIBA 11/2022
1	Apolipoprotein C-IIIIBA 11/2022
1	very low density lipoprotein triglycerideIBA 11/2022
1	TabletsIBA 11/2022
1	Glucagon-Like Peptide 1 (GLP 1)IBA 11/2021
1	Colchicine FDA LinkGeneric 01/2020
1	SolutionsIBA 01/2020
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2020

Therapy/Procedure

12	Therapeutics 11/2021 - 04/2008
3	Secondary Prevention 01/2019 - 08/2013
2	Surgical Amputation (Amputations) 03/2024 - 01/2020
2	Aftercare (After-Treatment) 12/2018 - 10/2018
2	Glycemic Control 12/2017 - 09/2009
1	Contraindications 01/2023
1	Critical Care (Surgical Intensive Care) 08/2021